Comparative effectiveness research: from clinical information to economic incentives.

  title={Comparative effectiveness research: from clinical information to economic incentives.},
  author={James C. Robinson},
  journal={Health affairs},
  volume={29 10},
  • James C. Robinson
  • Published 1 October 2010
  • Medicine, Political Science, Business
  • Health affairs
Comparative effectiveness research has been promoted as a way to control health care costs, but there has been less discussion of the mechanisms through which new evidence actually will influence physician practice, patient preference, and manufacturer investment. Public and private insurers use conditional coverage, consumer cost sharing, provider contracting, and drug payment policies to manage and direct the flow of resources into the health care system. This paper examines how each of these… 

Five reasons that many comparative effectiveness studies fail to change patient care and clinical practice.

Policy policies that encourage the development of consensus objectives, methods, and evidentiary standards before studies get under way and that provide strong incentives for patients and providers to use resources efficiently may help overcome some of these barriers and enable comparative effectiveness results to alter medical practice more quickly.

Value for Money in Health Spending

  • Medicine, Political Science
  • 2010
Current efforts to improve health care efficiency are examined, including tools that show promise in helping health systems provide the best care for their money, such as pay for performance, co-ordination of care, health technology assessment and clinical guidelines, pharmaceutical re-imbursement and risk-sharing agreements, and information and communication technology.

Comparative Effectiveness, Regulation, and the Evidence Base of Evidence-Based Healthcare

This paper explores how the kinds of data and data types and language used in the development of regulations and policies affect the quality of evidence and how these issues affect the production and use of evidence.

What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer.

Comparative implementation research is needed to inform the stakeholders considering diagnostic alternatives and the incongruent views of providers versus patient advocates and payers on involving patients in diagnostic decisions is a concerning challenge to utilizing the results of CER.

The politics of comparative effectiveness research: lessons from recent history.

Previous initiatives in CER are examined, highlighting their prescribed role in US health care, the reasons for their success or failure, the political lessons learned, and the issues that must still be addressed.

Evaluation of a program to improve diabetes care through intensified care management activities and diabetes medication copayment reduction.

To evaluate the short-term results of a diabetes-focused disease management program that included copayment reduction, care coordination, and patient goal setting, focusing on rates of evidence-based care processes and all-cause pharmacy and health care costs, 9,698 patients with diabetes were evaluated.

Toward effective health technology regulation

The thesis demonstrates that attaining good health technology regulation is complex and challenging, because of the inherent uncertainty regarding the benefits and risks of new technologies, their growing diversity and complexity, the limitations of existing study designs and assessment methods, and the increased demands placed on regulators to meet sometimes conflicting objectives.

MRI: From science to society

  • V. Lee
  • Education
    Journal of magnetic resonance imaging : JMRI
  • 2013
In this 2012 ISMRM Lauterbur Lecture, my goal is to challenge the members of the ISMRM to think critically about how we approach our research. From the perspective of a leader of an academic health



Evidence-based coverage policy.

The principles underlying evidence-based coverage policy and how they are applied by two major programs are discussed, the Technology Evaluation Center of the Blue Cross Blue Shield Association and the Medicare Coverage Advisory Committee.

Evidence that value-based insurance can be effective.

An examination of one value-based insurance design program found that the program led to reduced use of nondrug health care services, offsetting the costs associated with additional use of drugs encouraged by the program.

'Marginal medicine': targeting comparative effectiveness research to reduce waste.

This paper presents a conceptual framework for different evidentiary categories of what the authors call "marginal medicine" that could help clinicians, researchers, and policymakers align the results of comparative effectiveness research with efforts to identify opportunities to improve the value of health care services.

Insurers' strategies for managing the use and cost of biopharmaceuticals.

This paper examines strategies under development by health insurers to manage biopharmaceuticals, as their use spreads beyond rare diseases and academic sub-specialists to common conditions and

Consumer-driven health care: lessons from Switzerland.

The Swiss health care system holds important lessons, including evidence about its feasibility and equity, for the United States, which is now embarking on its own consumer-driven health Care system.

Hospital tiers in health insurance: balancing consumer choice with financial incentives.

The new network designs are described and the challenges they face in influencing consumers' behavior, incorporating information on clinical quality, and supporting medical education and uncompensated care are evaluated.

The end of fee-for-service medicine? Proposals for payment reform in Massachusetts.

  • R. Steinbrook
  • Medicine, Political Science
    The New England journal of medicine
  • 2009
A special commission has proposed that Massachusetts effectively end fee-for-service medicine, the predominant form of payment for health care services, and replace it with a system of global

Collective accountability for medical care--toward bundled Medicare payments.

This set of policies will create an environment that encourages and enables providers to accept bundled payments while also testing the feasibility of this payment design.

The end of managed care.

By default, if not by design, the consumer is emerging as the locus of priority setting in health care and the shift to consumerism is driven by a widespread skepticism of governmental, corporate, and professional dominance.